Get the Stockscreener App
1.5492
2.22%
-0.0308
Actinium Pharmaceuticals Inc stock is traded at $1.5492, with a volume of 50,018.
It is down -2.22% in the last 24 hours and up +1.64% over the past month.
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The company is also developing Actimab-A, which is in Phase II clinical trials for the treatment of patients newly diagnosed with AML over the age of 60, as well as in Phase I clinical trials in combination with CLAG-M for patients with relapsed or refractory AML; and Actimab-M that is in Phase I clinical trials for patients with refractory multiple myeloma. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.
See More
Previous Close:
$1.58
Open:
$1.54
24h Volume:
50,018
Relative Volume:
0.08
Market Cap:
$48.20M
Revenue:
$1.05M
Net Income/Loss:
$-48.82M
P/E Ratio:
-0.8466
EPS:
-1.83
Net Cash Flow:
$-47.49M
1W Performance:
-5.79%
1M Performance:
+1.64%
6M Performance:
+7.29%
1Y Performance:
-80.95%
1-Day Range:
$1.51
$1.565
1-Week Range:
$1.51
$1.69
52-Week Range:
$1.06
$8.64
Actinium Pharmaceuticals Inc Stock (ATNM) Company Profile
Name
Actinium Pharmaceuticals Inc
Sector
Industry
Phone
646-767-3870
Address
275 Madison Avenue, 7th Floor, New York, NY
Compare ATNM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATNM
Actinium Pharmaceuticals Inc
|
1.545 | 53.03M | 1.05M | -48.82M | -47.49M | -1.83 |
|
ONC
Beone Medicines Ltd Adr
|
246.34 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.12 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.31 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.12 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
491.29 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Actinium Pharmaceuticals Inc Stock (ATNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-07-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| May-14-24 | Initiated | Stephens | Overweight |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Feb-21-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-08-22 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-25-22 | Initiated | B. Riley Securities | Buy |
| Nov-05-20 | Initiated | Alliance Global Partners | Buy |
| Dec-06-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Oct-23-17 | Resumed | ROTH Capital | Buy |
| Sep-14-17 | Initiated | Maxim Group | Buy |
| Aug-25-16 | Initiated | ROTH Capital | Buy |
| Feb-29-16 | Initiated | H.C. Wainwright | Buy |
| Oct-15-15 | Initiated | FBR Capital | Outperform |
| Oct-01-14 | Initiated | MLV & Co | Buy |
| Jul-22-14 | Initiated | Canaccord Genuity | Buy |
View All
Actinium Pharmaceuticals Inc Stock (ATNM) Latest News
Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM)May 27, 2025 Deadline to JoinContact Levi & Korsinsky - PR Newswire
Shareholders of Actinium Pharmaceuticals, Inc. (ATNM): Protect Your Rights Before May 27, 2025Contact Levi & Korsinsky - ACCESS Newswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium - Business Wire
ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
2025-05-26 | Lost Money on Actinium Pharmaceuticals, Inc. (ATNM)? Urged to Join Class Action Before May 27, 2025Contact Levi & Korsinsky | NYSEAM:ATNM | Press Release - Stockhouse
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming DeadlinesATNM - PrimePublishers.com
ATNM Deadline: ATNM Investors with Losses in Excess of $100K Hav - GuruFocus
ATNM Deadline: ATNM Investors with Losses in Excess of $100K Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit - Morningstar
Class Action Lawsuit Filed: Actinium Pharmaceuticals, Inc. (ATNM)Join by May 27, 2025Contact Levi & Korsinsky - Stockhouse
Lost Money on Actinium Pharmaceuticals, Inc. (ATNM)? Contact Levi & Korsinsky to Join Class Action Before May 27, 2025 - ACCESS Newswire
ATNM DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Actinium Pharmaceuticals, ... - Eagle-Tribune
ATNM DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, - GlobeNewswire
ATNM DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 27 Deadline in Securities Class Action – ATNM - GlobeNewswire Inc.
Levi & Korsinsky Notifies Actinium Pharmaceuticals, Inc. (ATNM) Shareholders of Class Action Lawsuit and May 27, 2025 Deadline - ACCESS Newswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium - StreetInsider
ATNM Deadline: Rosen Law Firm Urges Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - The Joplin Globe
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium LawsuitATNM - The Malaysian Reserve
ATNM DEADLINE ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, - GlobeNewswire
Shareholders that lost money on Actinium Pharmaceuticals, Inc. (ATNM) Urged to Join Class ... - Bluefield Daily Telegraph
Shareholders that lost money on Actinium Pharmaceuticals, - GlobeNewswire
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium - marketscreener.com
Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) Over Securities ViolationsContact Levi & Korsinsky Today - ACCESS Newswire
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) Investor Alert: Deadline in Lawsuit on May 26, 2025 - openPR.com
Lost Money on Actinium Pharmaceuticals, Inc. (ATNM)? Urged to Join Class Action Before May 27, 2025Contact Levi & Korsinsky - ACCESS Newswire
Investors in Actinium Pharmaceuticals, Inc. (ATNM): Protect Your RightsContact Levi & Korsinsky Before May 27, 2025 - ACCESS Newswire
ATNM INVESTOR ALERT: Kirby McInerney LLP Reminds Actinium - GlobeNewswire
Contact The Gross Law Firm by May 27, 2025 Deadline to Join Class Action Against Actinium Pharmaceuticals, Inc. (ATNM) - The Malaysian Reserve
ATNM Lawsuit Alert! Class Action Lawsuit Against Actinium Pharmaceuticals - TipRanks
Investors in Actinium Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your RightsATNM - marketscreener.com
ROSEN, A TOP RANKED LAW FIRM, Encourages Actinium - GlobeNewswire
ATNM LAWSUIT ALERT: Levi & Korsinsky Notifies Actinium Pharmaceuticals, Inc. Investors of a ... - Bluefield Daily Telegraph
ATNM LAWSUIT ALERT: Levi & Korsinsky Notifies Actinium - GlobeNewswire
Dimensional Fund Advisors LP Cuts Stock Position in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World
ATNM Investors Have the Opportunity to Lead the Actinium Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - GlobeNewswire
ATNM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Actinium Pharmaceuticals, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Head-To-Head Survey: Xenetic Biosciences (NASDAQ:XBIO) & Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Did You Lose Money on Actinium Pharmaceuticals, Inc. (ATNM)? Levi & Korsinsky Urges Investors to Act Before May 27, 2025 - ACCESS Newswire
ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit - Morningstar
Investor Alert: Deadline Approaching to Join Actinium Pharmaceuticals, Inc. (ATNM) Class ActionContact Levi & Korsinsky - ACCESS Newswire
Investors who lost money on Actinium Pharmaceuticals, - GlobeNewswire
Actinium Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your RightsATNM - WV News
HC Wainwright Has Pessimistic Outlook of ATNM Q2 Earnings - Defense World
Recover Investment Losses: Levi & Korsinsky Files Class Action Against Actinium Pharmaceuticals, Inc. (ATNM) - ACCESS Newswire
Actinium Faces Derivative Suit Over FDA Application Claims - Law360
HC Wainwright Reaffirms “Buy” Rating for Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Levi & Korsinsky Notifies Shareholders of Actinium Pharmaceuticals, Inc.(ATNM) of a Class Action Lawsuit and an Upcoming Deadline - PR Newswire
Actinium Pharmaceuticals (NYSE:ATNM) Downgraded to “Sell” Rating by StockNews.com - Defense World
Shareholders That Lost Money on Actinium Pharmaceuticals, Inc. (ATNM) Should Contact Levi & Korsinsky About Pending Class ActionATNM - ACCESS Newswire
2025-05-12 | Shareholders That Lost Money on Actinium Pharmaceuticals, Inc. (ATNM) Should Contact Levi & Korsinsky About Pending Class ActionATNM | NYSEAM:ATNM | Press Release - Stockhouse
Shareholders that lost money on Actinium Pharmaceuticals, Inc.(ATNM) Urged to Join Class Action ... - Bluefield Daily Telegraph
Actinium Pharmaceuticals Inc Stock (ATNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):